Spots Global Cancer Trial Database for lurbinectedin (pm01183)
Every month we try and update this database with for lurbinectedin (pm01183) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | NCT02454972 | Advanced Solid ... | lurbinectedin (... | 18 Years - | PharmaMar | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | NCT02566993 | Small-cell Lung... | Lurbinectedin (... Doxorubicin (DO... Cyclophosphamid... Vincristine (VC... Topotecan | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | NCT02566993 | Small-cell Lung... | Lurbinectedin (... Doxorubicin (DO... Cyclophosphamid... Vincristine (VC... Topotecan | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | NCT02421588 | Ovarian Cancer | Lurbinectedin (... Pegylated lipos... Topotecan | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | NCT02454972 | Advanced Solid ... | lurbinectedin (... | 18 Years - | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT01951157 | Non-Small Cell ... | Docetaxel Gemcitabine Lurbinectedin (... | 18 Years - 75 Years | PharmaMar | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | NCT02454972 | Advanced Solid ... | lurbinectedin (... | 18 Years - | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | NCT02210364 | Metastatic Brea... Pancreatic Canc... Metastatic Colo... | lurbinectedin (... capecitabine | 18 Years - 75 Years | PharmaMar | |
| A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT01951157 | Non-Small Cell ... | Docetaxel Gemcitabine Lurbinectedin (... | 18 Years - 75 Years | PharmaMar | |
| Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors | NCT01970553 | Specific Advanc... | lurbinectedin (... Gemcitabine | 18 Years - 75 Years | PharmaMar | |
| Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors | NCT02451007 | Solid Tumors | lurbinectedin (... | - 65 Years | PharmaMar |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
